FoundationOne CDx is Now FDA Approved as a Diagnostic Tool For ALK+ Non-Small Cell Lung Cancer
source: pixabay.com

FoundationOne CDx is Now FDA Approved as a Diagnostic Tool For ALK+ Non-Small Cell Lung Cancer

FoundationOne CDx is a comprehensive genomic profiling test that is tissue based. It is used to identify individuals diagnosed with ALK+ non-small-cell lung cancer (NSCLC) who will be eligible for…

Continue Reading FoundationOne CDx is Now FDA Approved as a Diagnostic Tool For ALK+ Non-Small Cell Lung Cancer
Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer
source: pixabay.com

Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer

Brigatinib has been approved for the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC), as well as ALK+ NSCLC patients who have received prior treatment with crizotinib. While it…

Continue Reading Real-World Data on Brigatinib as a Treatment for ALK+ Non-Small Cell Lung Cancer
ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC
kalhh / Pixabay

ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

  According to a release on Biospace, the European Commission (EC) has approved Takeda Pharmaceutical's ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer…

Continue Reading ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC
EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer
oracast / Pixabay

EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer

The European Medicines Agency has recently released their positive opinion of ALUNBRIG, which is a treatment for anaplastic lymphoma kinase+ (ALK+) non-small cell lung cancer (NSCLC). They have recommended this…

Continue Reading EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer
ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment
source: pixabay.com

ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment

Since the 1940s oncologists have been focusing on tumors at the location in the body where the tumors originated. According to a recent FDA press release, this is the third…

Continue Reading ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment

New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

The FDA has just recently approved CYRAMZA as a treatment for those with hepatocellular carcinoma (HCC), who have been treated with sorafenib, and who have ≥400 ng/mL of alpha-fetoprotein (AFP).…

Continue Reading New Treatment Approved by FDA for Rare Form of Hepatocellular Carcinoma

New Partnership will Improve and Accelerate Patient Involvement in Lung Cancer Research

Pattern.Org Pattern.org was created by the Rare Cancer Research Foundation, a nonprofit dedicated to improving the lives of rare cancer patients by accelerating research. Pattern.org specifically, is a branch of…

Continue Reading New Partnership will Improve and Accelerate Patient Involvement in Lung Cancer Research